Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)Thomas Bachelot, A Wroński, Eva Ciruelos et al.|Annals of Oncology|2019Cited by 117
A phase III trial of taxotere and doxorubicin (AT) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in patients with unresectable locally advanced breast cancer: an interim analysisK. Bouzid, Nabeel Badri, S. Valdivia et al.|European Journal of Cancer|2001Cited by 10